Comparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chinese patients with type 2 diabetes mellitus

Journal of International Medical Research

Volumn 42, Issue 4, 2014, Pages 1002-1010

  Yang, Honghong ^a   Heng, Xueyuan ^b   Liang, Cuige ^b   Liu, Xiaomeng ^b   Du, Wenhua ^b   Li, Shoujie ^a   Wang, Yueli ^b   Dong, Qingyu ^b   Li, Wenxia ^b   Pan, Zhenyu ^c   Gong, Qian ^c   Gao, Guanqi ^b  

^a Yishui People's Hospital   (China)

^b LINYI PEOPLE'S HOSPITAL   (China)

^c Shandong Medical College   (China)

Author keywords

continuous subcutaneous insulin infusion; multiple daily injections; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; ISOPHANE INSULIN; METFORMIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ARTICLE; CHINESE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; BLOOD; CHINA; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; INJECTION; MALE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

BLOOD GLUCOSE; CHINA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INJECTIONS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84904663455     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060514533523     Document Type: Article

References (23)

1. Elbein SC,Wegner K,Kahn SE.Reduced beta-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds.Diabetes Care. 2000;23:221-227.
2. An YL,Gao Y,Zhu Q,et al.Features of insulin secretion and insulin resistance in newly diagnosed type 2 diabetes of different body mass indices.Zhonghua Yi Xue Za Zhi. 2009;89:1117-1121.
3. Juan CC,Fang VS,Kwok CF,et al.Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats.Metabolism. 1999;48:465-471.
4. McNay EC,Teske JA,Kotz CM,et al.Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: a model for weight gain with intensive insulin therapy.Am J Physiol Endocrinol Metab. 2013;304:E131-E138.
5. Bruttomesso D,Pianta A,Crazzolara D,et al.Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life.Diabet Med. 2002;19:628-634.
6. Bruttomesso D,Crazzolara D,Maran A,et al.In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.Diabet Med. 2008;25:326-332.
7. Hoogma RP,Hammond PJ,Gomis R,et al.Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.Diabet Med. 2006;23:141-147.
8. Didangelos T,Iliadis F.Insulin pump therapy in adults.Diabetes Res Clin Pract. 2011;93:S109-S113.
9. Gabir MM,Hanson RL,Dabelea D,et al.The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes.Diabetes Care. 2000;23:1108-1112.
10. Zhou J,Jia WP,Yu M,et al.The features of postprandial glucose state in type 2 diabetes mellitus.Zhonghua Yi Xue Za Zhi. 2006;86:970-975.
11. Gao GQ,Dong QY,Li SJ,et al.Investigation of the insulin dose and characteristics of continuous subcutaneous insulin infusion in Chinese people with type 2 diabetes.Diabetes Technol Ther. 2011;13:1135-1138.
12. Weissberg-Benchell J,Antisdel-Lomaglio J,Seshadri R.Insulin pump therapy: a meta-analysis.Diabetes Care. 2003;26:1079-1087.
13. Doyle EA,Weinzimer SA,Steffen AT,et al.A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.Diabetes Care. 2004;27:1554-1558.
14. Torres I,Ortego J,Valencia I,et al.Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.Exp Clin Endocrinol Diabetes. 2009;117:378-385.
15. Siebenhofer A,Plank J,Berghold A,et al.Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.Cochrane Database Syst Rev. 2006;:CD003287-CD003287.
16. Plank J,Siebenhofer A,Berghold A,et al.Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus.Arch Intern Med. 2005;165:1337-1344.
17. Phillip M,Battelino T,Rodriguez H,et al.Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care. 2007;30:1653-1662.
18. Monami M,Lamanna C,Marchionni N,et al.Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis.Exp Clin Endocrinol Diabetes. 2009;117:220-222.
19. Kesavadev J,Balakrishnan S,Ahammed S,et al.Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes.Diabetes Technol Ther. 2009;11:517-521.
20. Kelley D,Mokan M,Veneman T.Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus.Metabolism. 1994;43:1549-1557.
21. Yki-Järvinen H,Helve E,Sane T,et al.Insulin inhibition of overnight glucose production and gluconeogenesis from lactate in NIDDM.Am J Physiol. 1989;256 (Pt 1): E732-E739.
22. Mudaliar SR,Lindberg FA,Joyce M,et al.Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.Diabetes Care. 1999;22:1501-1506.
23. Suzuki D,Toyoda M,Kondo M,et al.Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes.Tokai J Exp Clin Med. 2012;37:35-40.